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To the Editor: Priority claims are often difficult to
substantiate. Such is the case with the Canadian school of
nocturnal hemodialysis, which has continuously refused to
recognize that they were not the first to carry out overnight
hemodialysis. Thus, the statement ‘nocturnal hemodialysis, a
technique first developed in the 1970s’ published in Kidney
International,1 cannot be allowed to go unchallenged. On
numerous occasions, I have pointed out to the Canadian
nocturnal hemodialysis school that frequency of hemodialysis
does not permit claims to originality in the use of the night
for hemodialysis.2 We were the first to report the successful
use of unattended overnight hemodialysis in 19633–5 and this
was recognized by Scribner6 in 1966 when he stated ‘Shaldon
has taken a big step forward in this respect by demonstrating
the feasibility of unattended nighttime hemodialysis’. The
development of the high low venous pressure monitor, which
was the key to safe overnight hemodialysis was also reported
in the Lancet in 1963.7 As regards frequency, we started in
1961 with two dialyses per week, but very soon increased the
frequency to three, four, and even five dialyses per week. The
system was reported in detail at the first meeting of the
European Dialysis and Transplant Association in Amsterdam
in 1964.8
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Not being formal members of the Canadian School of
Nocturnal Hemodialysis, we were unaware that there was
controversy as to who first pioneered nocturnal hemo-
dialysis. Shaldon makes a compelling argument that
nocturnal hemodialysis was first performed in the 1960s.1
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To the Editor: We have recently reported the CARTER study1
and speculated that the greater antiproteinuric effect of
cilnidipine may be due to the N-type calcium channel
blockade. To confirm the CARTER study from another
aspect, we focused on pharmacological differences between
these two dihydropiridine compounds. Free radicals are
necessary in physiological processes, but loss of redox
homeostasis contributes to proinflammatory and profibrotic
pathways in the kidney, which in turn lead to reduced
vascular compliance and proteinuria.2 Dihydropiridine
derivatives act as lipophilic chain-breaking antioxidants.3
However, Uesawa and Mohri4 reported a big difference
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Figure 1 | Comparative inhibitory effect of cilnidipine and
amlodipine on superoxide production from cultured human
mesangial cells (HMSCs). Cilnidipine (black circles) and
amlodipine (red circles) were added at the same time with
ionomycin to the incubation medium of HMSCs. Effects of
pretreatment with cilnidipine and amlodipine are shown as
triangles (cilnidipine, black triangles; amlodipine, red triangles).
HMSCs were pretreated with cilnidipine or amlodipine 1 h before
ionomycin stimulation. *Po0.05 vs red circle. **Po0.05 vs black
circle. Values are mean±s.e.m. (n¼ 8).
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in their lipophilicity, with cilnidipine showing stronger
lipophilicity than amlodipine. These results suggest that
differences in antioxidant activity and lipophilicity may
determine antiproteinuric effect. We compared antioxidant
activity of cilnidipine and amlodipine by measuring iono-
mycin-stimulated superoxide production in cultured human
mesangial cells. Cilnidipine showed a significantly higher
antioxidant activity than amlodipine (Figure 1). As cilnidi-
pine has high lipophilicity, we speculated that pretreatment
of human mesangial cells with cilnidipine might augment
antioxidant activity by penetrating into the cells. With 1-h
pretreatment, the concentration–response curve of cilnidipine
significantly shifted to the left (Figure 1). However, we found
no shift in that for amlodipine. Molecular weight of
cilnidipine is 492.52, and Cmax of cilnidipine is between
9.6±1.6 and 16.5±7.9 ng/ml (1.95±0.32 108 and
3.35±1.6 108 mol/l). These results showed that cilnidi-
pine had stronger antioxidant activity than amlodipine
around clinical plasma concentration (108 mol/l). We
propose that superior antioxidant activity of cilnidipine as
compared to amlodipine might, at least in part, explain the
results of CARTER study.
1. Fujita T, Ando K, Nishimura H et al. Antiproteinuric effect of the calcium
channel blocker cilnidipine added to renin–angiotensin inhibition in
hypertensive patients with chronic renal disease. Kidney Int 2007; 72:
1543–1549.
2. Nistala R, Whaley-Connell A, Sowers JR. Redox control of renal function
and hypertension. Antioxid Redox Signal 2008; 10: 2047–2089.
3. Mak IT, Weglicki WB. Comparative antioxidant activities of propranolol,
nifedipine, verapamil, and diltiazem against sarcolemmal membrane lipid
peroxidation. Circ Res 1990; 66: 1449–1452.
4. Uesawa Y, Mohri K. Relationship between lipophilicities of 1,4-
dihydropyridine derivatives and pharmacokinetic interaction strengths
with grapefruit juice. Yakugaku Zasshi 2008; 128: 117–122.
Keiichi Hishikawa1, Osamu Takase1, Mana Idei1 and Toshiro
Fujito2
1Department of Clinical Renal Regeneration, Graduate School of Medicine,
University of Tokyo, Tokyo, Bunkyo-ku, Japan and 2Department of
Nephrology and Endocrinology, University of Tokyo, Tokyo, Japan
Correspondence: Keiichi Hishikawa, Department of Clinical Renal
Regeneration, Graduate School of Medicine, University of Tokyo, Hongo
7-3-1, Tokyo, Bunkyo-ku, Japan. E-mail: hishikawa-tky@umin.ac.jp
Kidney International (2009) 76, 229–231 231
l e t t e r t o t h e e d i t o r
